Read More

Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study Of Allosteric BCR-ABL Inhibitor TERN-701 In Adult Healthy Volunteers And Highlights Potential For Competitive Differentiation

Ability to dose TERN-701 without regard to food represents a key potential differentiator within the allosteric BCR-ABL inhibitor classPharmacokinetic data show no clinically significant difference in exposure

TERN

Read More

Domino’s Pizza Has Displayed A Strong Start To 2024, Says Analyst

Discover why TD Cowen analyst Andrew Charles upholds a Buy rating on Domino's Pizza Inc (NYSE:DPZ) with a $550 price target, despite challenges. DPZ's Q1 FY24 sales soar 6%, hitting $1.085 billion, outstripping projections. The EPS of $3.58 surpasses expectations, thanks to supply chain enhancements and reduced expenses, despite losses from DPC Dash investment adjustments.

DPZ